Conflict of interest: Dr. Bojara is a physician proctor for CoreValve (Medtronic, Minneapolis, Minnesota). The remaining authors report no conflicts.
Valvular and Structural Heart Diseases
Clinical outcome of transcatheter aortic valve implantation in patients with low-flow, low gradient aortic stenosis†
Article first published online: 5 AUG 2011
Copyright © 2011 Wiley Periodicals, Inc.
Catheterization and Cardiovascular Interventions
Volume 79, Issue 5, pages 693–701, 1 April 2012
How to Cite
Gotzmann, M., Lindstaedt, M., Bojara, W., Ewers, A. and Mügge, A. (2012), Clinical outcome of transcatheter aortic valve implantation in patients with low-flow, low gradient aortic stenosis. Cathet. Cardiovasc. Intervent., 79: 693–701. doi: 10.1002/ccd.23240
- Issue published online: 27 MAR 2012
- Article first published online: 5 AUG 2011
- Accepted manuscript online: 29 JUL 2011 11:12AM EST
- Manuscript Accepted: 15 MAY 2011
- Manuscript Received: 29 MAR 2011
- VALV, valvular heart disease;
- HEMO, hemodynamics;
- MYOP, cardiomyopathy
Background: Low-flow, low-gradient aortic stenosis is associated with relevant postoperative mortality whereas conservative management results in dismal prognosis. We present the initial experience of low-flow, low-gradient aortic stenosis treated with transcatheter aortic valve implantation (TAVI). Methods: From June 2008 to December 2010 167 consecutive patients with native severe aortic stenosis and an excessive operative risk underwent TAVI. Of these, 15 patients presented with low-flow, low-gradient aortic stenosis (aortic valve area < 1 cm2, left ventricular (LV) ejection fraction < 40%, aortic mean gradient < 40 mm Hg). The CoreValve prosthesis 18-F-generation (Medtronic, Minneapolis, Minnesota) was inserted retrograde. Clinical follow-up and echocardiography were performed 6 months after procedure. Results: Patients with low-flow, low-gradient aortic stenosis (mean LV ejection fraction 32 ± 6%, mean aortic gradient 27 ± 7 mm Hg) had higher all-cause mortality 6 months after TAVI compared to patients without low-flow, low-gradient aortic stenosis (33% vs. 13%, P = 0.037). In the surviving 10 patients with low-flow, low-gradient aortic stenosis, LV ejection fraction increased (34 ± 6% before vs. 46 ± 11% 6 months after TAVI, p = 0.005) and more distance covered in the 6-minute walk test (218 ± 102 meters before vs. 288 ± 129 meters 6 months after TAVI, p = 0.038). Conclusion: Our study suggests that TAVI is feasible in patients with severe co-morbidities and low-flow, low-gradient aortic stenosis. Within the first 6 months after treatment all-cause mortality was considerable high, but the surviving patients showed symptomatic benefit and significant improvement of myocardial function and exercise capacity. © 2011 Wiley Periodicals, Inc.